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Population – Patients admitted for substance use disorder treatments 
from injection drug use (IDU) with positive Hepatitis C
Intervention  – The states must prevent opioid misuse and addiction, 
reduce overdose deaths and other harmful consequences, improve 
opioid addiction treatment, and improve addiction care in the criminal 
justice system.
Comparison – Patients who report positive Hepatitis C without 
abusing opioids through IDU
Outcome – Reducing HCV infections by ending the opioid epidemic
Time – Now!! Prevent and help people who abuse opioids through IDU 
(injection drug use)
PICOT Statement
• More awareness from the states of the opioid epidemic and risks that 
come with it. 
• Integrated health services that include syringe service programs, 
medication-assisted treatment, and comprehensive HCV testing and 
linkage to care and treatment of HCV-infected PWID are essential to 
reduce prevalence and incidence among the population.
• Population based screening of young adults may be a reasonable 
strategy for identifying infected people and connecting them to 
treatment, as has been done among baby boomers. 
• Development of new virologic-detection assays, available as point-of-
care tests, will improve detection of new infections while simplifying 
clinical monitoring.
• Effective HCV vaccine
Interventions
• Drug overdose is now the leading cause of death in the United 
States among people under age 50. Opioid related death rates 
keep rising over the U.S. and in nearly almost every state.
• A significant portion of opioid related addiction, overdose, and 
death is now related to the use of heroin and deadly synthetic 
opioids like fentanyl and carfentanil, which are not bjeing
prescribed by physicians nor monitored through PDMPs. Rather, 
these illicit drugs often are cheaper and more accessible than 
prescription opioids and the more potent and deadly versions of 
them are increasingly mixed into heroin, cocaine, and other drugs, 
most of the time without the knowledge or awareness of those 
who use them.
• Approximately 15.7 percent of total state spending goes toward 
substance use and addiction; 94 percent of that amount is spent 
on addressing the consequences of substance use and addiction 
rather than on prevention, treatment, or research.
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• Underreporting of cases of acute HCV infection is common.
• The case definition for acute infection only describes people with 
signs and symptoms of illness, yet most acute HCV infections are 
asymptomatic.
• The TEDS (Treatment Episode Data Set) data that was used has 
limitations because treatment is provided to only a fraction of 
persons with SUD in the United States. It is likely that there is a 
larger number of persons with SUD who inject drugs than what is 
reported. The TEDS analysis also could have counted the same 
person for multiple readmissions. Reporting varies in each state 
to TEDS, so the state-specific trends and state-by-state 
comparisons should be interpreted with caution.
Background Information
The opioid epidemic is a stark 
reminder of the consequences of a 
societal problem that was not 
brought into attention for years. 
Most of the reason the problem 
was never addressed was because 
of the stigma associated with drug 
use and the reluctance to confront 
it as a public health problem.
From 2013 on, the number of HCV-
related deaths in the U.S. has 
exceeded the number of deaths 
associated with HIV and 59 other 
infectious diseases combined. 
Hepatitis C is rapidly growing 
throughout the U.S. and is the most 
common blood-borne infection 
now. Injection drug use (IDU) is the 
primary risk factor for HCV 
transmission and is the leading 
cause of incidence in the United 
States.
Summary of Studies
Significant increases in opioid 
injection mirrored those for 
reported cases of acute HCV 
infection among demographic 
subgroups. 
• Theoretical models suggest that combining HCV treatment with 
risk-reduction measures is the most effective way to prevent 
transmission among injection-drug users.
• An effective vaccine could reduce the risk of HCV transmission if 
it were routinely provided to people before the onset of high-
risk behaviors.
• To make significant and meaningful progress in ending the 
opioid crisis, the states need to assume the role of adopting a 
public health approach to the opioid crisis, and to addiction 
more generally. States can build on the momentum at the 
federal level to implement a public health approach to the 
problem, using the funds that have been made available to them 
through recent landmark pieces of legislation.
Hepatitis C (HCV) is rapidly growing and has become the most common 
blood-borne infection throughout the United States.  The objective of 
this study was to compare trends in rates of injection drug use (IDU), 
specifically opioid injection, with national trends in the incidence of 
acute HCV infection to assess whether these events correlated over 
time. The methodology was a literature review.  To test for trends 
researchers calculated the annual incidence rate, demographics, and 
risk characteristics of reported cases of acute HCV infection using 
surveillance data from 2004 to 2014. They also analyzed the annual 
percentage of admissions to substance use disorder treatment facilities 
reporting injection drug use for the same time period by type of drug 
injected and demographic characteristics. Using the six sources, the 
results showed that significant increases in opioid injection mirrored 
those for reported cases of acute HCV infection among demographic 
subgroups. Injection drug use was the primary risk factor for HCV 
transmission and the leading cause of incidence in the U.S.  
Interventions were identified to help end the “opioid epidemic”, which 
then in return would reduce positive cases of HCV infections.
